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Summary.-An immunological profile has been serially studied in 72 patients with
advanced breast cancer during the course of a randomized trial of chemotherapy and
hormonal manipulation. DNCB+ patients were more likely to respond to either
therapy, but no other test was predictive of response. In the follow-up period all
chemotherapy patients had a reduction in white-cell count which was significantly
greater in those responding to treatment. None of the other tests (phytohaem-
agglutinin response, immunoglobulins G, A and M, or Mantoux test) demonstrated
changes that could be related to treatment or response, but there was a gradual
unexplained fall in IgM levels in all groups the study progressed. It is concluded
that the chemotherapeutic regimen (cyclophosphamide, vincristine, adriamycin and
5-fluorouracil) is relatively non-immunosuppressive, and that hormonal therapy
(oophorectomy, tamoxifen or androgens) had no detectable effect on the immune
response.
CHEMOTHERAPY now has an established
part to play in the management of breast
cancer, even to the extent that it has been
suggested that endocrine manipulation is
obsolete (Edelstyn & Macrae, 1973).
Chemotherapy is not without potentially
harmful side effects; one which occasions
much concern is immunodepression. This
could be important not only in the failure
to control infection but in terms oftumour
biology (Harris, 1975). This concern has
arisen from the use of similar drugs in
transplantation surgery where immuno-
suppression is well documented and where
the patients are known to be at an added
risk for developing cancer (Wilson et al.,
1968). The situation is less clear with the
intermittent regimes of these drugs when
used for cancer therapy, and there is con-
flicting evidence for second malignancies
in patients with Hodgkin's disease.
Arseneau et al. (1972) described a signifi-
cantly increased risk of developing a
second cancer, but Sutherland et al. (1975)
were unable to confirm this. When the
Cardiff Breast Clinic instituted a random-
ized trial of chemotherapy and endocrine
therapy in women with advanced breast
cancer the opportunity was taken to study
the changes that occurred in an immune
profile, to monitor the effects of therapy
on immunocompetence and to see whether
immune status predicted or reflected
response to treatment.
PATIENTS AND METHODS
WAomen with advanced breast cancer who
had not had previous systemic treatment
were randomly allocated to receive either
endocrine manipulation or chemotherapy
(Priestman et al., 1977). Endocrine therapy,
selected on the basis of previous experience
and depending on menopausal status and ex-
tent of disease, was predetermined by the
protocol (premenopausal women-oophor-
ectomy; postmenopausal women with pre-
dominantly soft tissue disease-tamoxifen;
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postinenopausal women with predominantly
skeletal disease-androgens). The chemo-
therapeutic regimen consisted of doxorubicin
60 mg, cyclophosphamide 750 mg, 5-fluoro-
uracil 750 mg, and vincristine 2 mg, by i.v.
injection on one day every 3 weeks. Suitable
safeguards with regard to dosage and toxic
effects were written into the protocol. The
criterion for response was a minimum of50%
reduction of all measurable lesions lasting for
at least 3 months.
An immunological profile was assessed
before treatment began and 6, 12, and 26
weeks after it started. The profile consisted of
delayed hypersensitivity reactions to a new
antigen, dinitrochlorobenzene (DNCB), and
a recall antigen, tuberculin, total white cell
and differential count, lymphoblastogenic
stimulation in response to phytohaem-
agglutinin (PHA) and measurements of the
immunoglobulin classes G, A and M.
Bolton et al. (1976) have described our
technique for the DNCB test but, because of
the relatively small numbers in each group,
responses have been reported as only negative
or positive. Tuberculin has been used as a
recall antigen using 0 1 ml of 1:1000 PPD as
the challenge dose, unless previous history or
experience suggested that a strength of
1:10,000 should be used. When Grade IV
responses to these tests were obtained, further
tests were omitted. The total white-cell count
in peripheral blood was recorded on a Coulter
counter, and a differential count of 200 cells
used to derive the lymphocyte count. The
PHA test was carried out as described by
Whitehead et al. (1975). The response to 3
doses was expressed as a response curve,
which for each test is recorded as normal
(positive) when there is maximal response to
a dose of0-8 mg/ml PHA, or abnormal (nega-
tive) when the maximal response is to a
higher dose (4 mg/ml). The immunoglobulin
classes G, A and M were measured using a
standard radial immunodiffusion technique
(Mancini et al., 1965).
Patients failing to respond to treatment
were excluded from further study when
alternative treatment schedules were begun.
Statistical analysis is by Student's t test or
by Chi-square test as appropriate.
RESULTS
Immunological assessment was carried
out on all but the first 20 ofthe 92 patients
TABLE I.-Comparison of endocrine and
chemotherapeutic groups before treatment
Chemotherapy
(35)
Age (years) 58±-8
DNCB+*
Mantoux+*
PHA+*
Total white-cell count
(cells/mm3 x 10-3)
% lymphocytes
Lymphocyte count
(cells/mm3 x 10-3)
IgG (mg/100 ml)
IgA (mg/100 ml)
IgM (mg/100 ml)
20/28 (70%)
14/28 (50%)
14/30 (47%)
6-49± 1-29
Endocrine
therapy
(37)
60±11
15/31 (48%)t
6/32 (19%)t
15/31 (48%)
7-06±2-52
21 ± 12 17±8
1-40±0-81 1-14±0-6C
1438±415
226± 138
134±83
1491± 375
252± 132
134±90
* Number of positive/total observations.
t P<005 by Chi-square test.
TABLE II.-DNCB reaction: No. positive/
No. tested
Chemotherapy
Re- No re-
sponse* sponse*
Pre-treatment 13/14t 7/14t
6 weeks 10/14 5/9
12 weeks 9/13 2/5
26 weeks 7/8 1/1
Endocrine
therapy
Re- No re-
sponse* sponse*
4/7 11/24
7/7 7/16
5/7 4/9
4/6 2/3
* In this and subsequent tables response/no
response refers to objective response of tumour
when assessed at 12 weeks.
t P < 0-05 between response and no response to
chemotherapy.
TABLE III.-Mantoux reaction
Pre-treatment
6 weeks
12 weeks
26 weeks
Chemotherapy
Re- No re-
sponse sponse
7/13 7/14
5/12 2/9
4/13 1/5
4/9 0/1
Endocrine
therapy
A
Re- Nore-
sponse sponse
2/7 4/24
1/6 5/16
2/7 1/9
1/6 0/3
described by Priestman et al. (1977). The
remaining 72 were studied consecutively.
Thirty-five patients received chemo-
therapy and 37 hormonal manipulation.
Table I shows the pre-treatment assess-
ment ofthe patients. There was no signifi-
cant difference between the groups except
that DNCB+ and Mantoux+ patients
occurred more frequently in the chemo-
therapy group.
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TABLE IV. PHA reaction of lymphocytes
in vitro: NSo. with normal reaction/INo.
tested
Pre-treatment
(6, weeks
12 weeks
26 weeks
Chemotherapy
C-
Re- No re-
sponse sponse
7/17 7/13
7/16 4/9
5/15 5/9
3/7 1/2
Endocrine therapy
Only 7 patients were
Endocrine
therapy
Re- No re-
spoinse sponse,
4/5 11/26
2/5 7/19
:3/5 5/7
2/4 2/3j
classified as
having responded to endocrine manipula-
tion. None of the pre-treatment tests
were able to predict a response to endo-
crine therapy, nor were there any statistic-
ally significant differences in immuno-
logical status (Tables II-X) during the
period of observation. There was a trend
for the IgM level to fall regardless of the
clinical response, and this reached a
statistically significant low level at 3
months when responders and non-
responders are considered together.
Patients responding to treatment restore
their DNCB responses (Table II) to
normal, and subsequently tend to revert
to negative as their disease reappears.
Chemotherapy
Comparison of the 18 patients who
responded to chemotherapy with those
who did not (17 patients) shows that there
were significantly (P<0.05) more patients
who were DNCB+ (before treatment)
amongst the responders (Table II). The
pre-treatment values for the total white-
cell count (t-1.69; P<0 05) shows that
the responders had significantly lower
TABLE VI. °0 Lymphocytes: (mean+Es.d.)
Endocrine
Chemotherapy therapy
C- -i C--i
Re- No re- Re- No re-
sponse sponse sponse sponse
Pre-treatment 22±1:3 20±1:3 16 7 18 10
12 weeks 2:3±11 262+1:3 1 (; 189 11
26 weeks 18 11 19-3:3 13 5 17 15
levels, but no difference was found for the
other variables (Tables III-X). There was
a fall in the total white-cell count in both
responders and non-responders after
chemotherapy. The total white-cell count
was significantly lower in the responders
(t 2-76; P<001) at 6 weeks, and this
difference was maintained throughout the
study. Although there was a fall in the
lymphocyte count this did not reach
statistical significance until the last obser-
vation in the responding group (Table
VII). The fall in the non-responders did
not reach statistical significance. Again, a
continuing fall in the levels of IgM was
seen during the study, irrespective of the
response to treatment, and this reached a
statistically significant level (P<0.05)
after 12 weeks.
The DNCB test was more frequently
positive in those who responded to either
treatment; 17/35 positive patients re-
sponded, while only 4/24 negative patients
responded (x2- 632; P<0-01). None of
the other tests in this profile had any
predictive value in response.
DISCUSSION
It is difficult to explain the differences
in the immunological status of the two
treatment groups before therapy. Since
TABLE V.-Total white-cell counts (cells/mm?3 x 10-3): mean + s.d.
Chemotherapy Endocrine therapy
C- -h C-A
Response No response Respon1se No respoInse
PIe-tieatment 6-12+1-16 6-92±1-34 7-60± 1-68 6-944-2-68
6weeks 4-45±1 40* 5-88 0-47t 7-84±2-02 7-51---2-9()
12weeks 4.34±1 27* 5-91 1-37t 7-47 2-36 6-35±1-94
26 weekhs 4-90±1 88* 5-50±0-89 7-77 2-00 6-53 - 1-67
* P<0-01 Compared to pretreatment WBC in responders.
t P<0-05 Compared to responders at the same time after treatment started.
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TABLE VII.-Absolute lymphocyte count (cells/mm3 x 10-3): mean + s.d.
Chemotherapy
Response No response
Pre-treatment 1-37±0-78 1-43±0-87
6 weeks 0-96±0-45 1-39±0-63
12 weeks 0-95±0-58 1-16±0-95
26 weeks 0-79±0-51* 1-15±0-07
* P<005 with respect to pre-treatment values.
Endocrine therapy
Response No response
1-21±0-67 1-13±0-60
1-16±0-48 1-23±0-64
1-28±1-04 1-03±0-42
1-03±0-47 1-15±0-78
TABLE VIII.-Immunoylobulin-IgG: mean + s.d. (mg/100 ml)
Chemotherapy
t A
Response No response
1464±471 1405±343
1332±371 1435±277
1361±388 1195±262
1311 ±453 1081±339
Endocrine therapy
Response No response
1275±373 1539±365
1319±194 1519±382
1407±291 1392±320
1307±309 1384±565
TABLE IX.-Immunoglobulin-IgA (mg/100 ml): mean + s.d.
Chemotherapy
Response No response
191±82 272± 181
182±62 196±89
187±65 189±100
178± 79 253±135
Endocrine therapy
Response No response
270± 179 248± 128
243±112 217±98
270±141 212±84
267±153 228±155
TABLE X.-Immunoglobulin-IgM (mg/100 ml): mean + s.d.
Chemotherapy
Response No re'
Pre-treatment 125±56 146d
6 weeks 97±52 1034
12 weeks 85±37* 69:
26 weeks 73±37* 71-
* P<0 05 with respect to pre-treatmer
the treatments were randomly allocated
and the patients studied were consecu-
tively entered into the trial, it is possibly
a chance finding related to the small
numbers studied.
With the sole exception of the DNCB
response, the tests used in the immuno-
logical profile failed to identify the
patients likely to respond to therapy. This
finding may be equated with the observa-
tion that only the DNCB response corre-
lated with disease stage in breast cancer
(Bolton et al., 1976). In a similar way we
found that in patients receiving chemo-
therapy a significant lowering of the total
white-cell and lymphocyte counts is asso-
ciated with a clinical response (O'Bryan
Endocrine therapy
Response No response
117±111 136±88
91±54 137±76
77±41 96±49
87±56 92±37
et al., 1977). Whether this is a reflection of
the closeness of toxic and therapeutic
doses, or whether the lowering of the
white-cell count is an epiphenomenon
secondary to a reduction in tumour bulk
remains unclear. Mott (1973) advanced
the hypothesis that immunodepression
occurring during chemotherapy might be
beneficial, perhaps by exerting a specific
effect on suppressor cells. Our findings that
the peripheral white-cell count and
lymphocyte count fall significantly would
be consistent with this hypothesis.
Whilst the effect of chemotherapy on
the immune system, especially in respect
of transplantation, has been extensively
studied, the effects of hormonal manipula-
Pre-treatment
6 weeks
12 weeks
26 weeks
Pre-treatment
6 weeks
12 weeks
26 weeks
679680 D. J. T. WEBSTER EY AL.
tion on lymphocyte numbers and function
have been relatively ignored, although the
effect onthe monocyte/macrophage system
has been more extensively studied (Baum,
1975). Yonemoto et al. (1977) have demon-
strated that a good clinical response to
adrenalectomy was associated with a rise
in T-cell count and a decrease in blocking
factor, but were unable to elucidate cause
and effect. Our studies have shown little
change in immune status of patients who
respond, in spite oftheir improved clinical
state. Franks et al. (1978) have recently
reported that patients with a low level of
circulating lymphocytes are less likely to
respond to hormone therapy. However, he
didnot demonstrate anysignificant change
in levels with treatment.
The progressive fall in 1gM in both
treatment groups during the study re-
mains an enigma, since it has not been
found to relate to disease stage (Bolton et
al., 1976) nor does it appear to be related
to treatment or response in this study. It
does not seem to be a laboratory-related
phenomenon, since the results from the
laboratory controls did not change during
the period of the study.
We find that this chemotherapeutic
regime is lacking in severe short-term
immunosuppressive effects, and indeed
clinical improvement is associated with
increased DNCB reactivity in most
patients in remission at 6 months. The
long-term effects of the myelosuppression
remain unknown, but there seems to be a
trend for the white-cell count to increase
with time.
We gratefully acknowledge the help of Dr R. H.
Whitehead and Dr J. W. Keyser with the laboratory
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